PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 NGTIT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnzVWVKSzVyPUCuNFIzPzZizszN NFewOHVUSU6JRWK=
CHP-212 NWHqPHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfiXYlKSzVyPUCuNFI5QDVizszN MX\TRW5ITVJ?
EoL-1-cell NYfuZoNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;HSo5KSzVyPUCuNFQyPTJizszN M2fVTHNCVkeHUh?=
DU-4475 NUH3doJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nDNmlEPTB;MD6wO|U6QSEQvF2= MVHTRW5ITVJ?
MMAC-SF MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMUC5O|Qh|ryP MVLTRW5ITVJ?
AGS MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e2UGlEPTB;MD6xNVcyOyEQvF2= MnfRV2FPT0WU
M14 M4mzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMUW0Olgh|ryP MmrsV2FPT0WU
CP50-MEL-B NY\UWoZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjpTWM2OD1yLkG3NlU1KM7:TR?= M3\6fnNCVkeHUh?=
C32 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMUmwO|Ih|ryP MVzTRW5ITVJ?
KMOE-2 M2HtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMUm3PVUh|ryP MkT1V2FPT0WU
A101D NUXIcIFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXLOohKSzVyPUCuNlE1KM7:TR?= NX7DeYZsW0GQR1XS
KM12 NX;BR|kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXSTWM2OD1yLkK0NFU4KM7:TR?= NVjhOYJOW0GQR1XS
HSC-4 NWDzOJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKz[lFKSzVyPUCuNlQ{QTVizszN NU[3XldSW0GQR1XS
NOMO-1 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzpTWM2OD1yLkK1O|QzKM7:TR?= MkT0V2FPT0WU
MZ7-mel Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzk[nBKSzVyPUCuNlY{PCEQvF2= MV3TRW5ITVJ?
ACN NYK4emJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\3RlVKSzVyPUCuNlY4OzdizszN M3ftdHNCVkeHUh?=
MEL-HO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\yRWdKSzVyPUCuNlc3PTJizszN NHHjTFZUSU6JRWK=
BHT-101 NW\YSottT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHWTWM2OD1yLkK4OlA3KM7:TR?= NVTBeY5EW0GQR1XS
SK-MEL-28 NV6wWHhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHtXldKSzVyPUCuN|A1ODlizszN MX\TRW5ITVJ?
KG-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwM{C2Olgh|ryP M3rQNHNCVkeHUh?=
COLO-679 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HSd2lEPTB;MD6zNlczKM7:TR?= MVXTRW5ITVJ?
SK-MEL-24 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLKTWM2OD1yLkOyPFE{KM7:TR?= NUOzdnJlW0GQR1XS
G-361 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwM{[3PVUh|ryP NX3kXJRtW0GQR1XS
KY821 M2XyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknoTWM2OD1yLkO3PVEh|ryP M2q4bXNCVkeHUh?=
KASUMI-1 NVX6Z|JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TyTWlEPTB;MD6zPVkh|ryP MlrPV2FPT0WU
HL-60 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK0[nI5UUN3ME2wMlQyOTB5IN88US=> MkLWV2FPT0WU
K5 M17pZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwNEOxNVch|ryP NGDiTFZUSU6JRWK=
KU812 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme1TWM2OD1yLkS1Nlk6KM7:TR?= MVTTRW5ITVJ?
SH-4 NWjVeWRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPnOYd[UUN3ME2wMlQ3OjV4IN88US=> NGCweZBUSU6JRWK=
HTC-C3 M4fPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwNE[1N|Eh|ryP NXXjV|NkW0GQR1XS
CP66-MEL M3vqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jkcWlEPTB;MD60PFgxQSEQvF2= NUnKS|Z[W0GQR1XS
WM-115 NIX2[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrobnFKSzVyPUCuOFkzPTdizszN MWPTRW5ITVJ?
A2780 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNEm4NlMh|ryP MVfTRW5ITVJ?
P12-ICHIKAWA NF3jZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCzTWM2OD1yLk[xNlIyKM7:TR?= NFrCfm1USU6JRWK=
HMV-II MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILnVllKSzVyPUCuOlQ1PjVizszN M{DBPHNCVkeHUh?=
HT-144 NX3OWnhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwNkS2OVch|ryP NIjBUYhUSU6JRWK=
LB2518-MEL Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLkTWM2OD1yLkexOlMzKM7:TR?= MlnLV2FPT0WU
NCI-SNU-1 M2nqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwN{W0N|Mh|ryP NHuw[pRUSU6JRWK=
C2BBe1 M3zjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\MSmlEPTB;MD64NVAzOyEQvF2= NWG0bHZ{W0GQR1XS
PSN1 NFfNZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnIT3c6UUN3ME2wMlk3OTl4IN88US=> NYrQWlJuW0GQR1XS
UACC-257 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwOU[0O|Mh|ryP MWnTRW5ITVJ?
RVH-421 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwOUexPEDPxE1? MWDTRW5ITVJ?
GP5d MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzqZpRpUUN3ME2wMlk5OzB6IN88US=> NVXBUYs2W0GQR1XS
TYK-nu NHTUfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;6dWlEPTB;MT6wN|E4OiEQvF2= MXHTRW5ITVJ?
SK-N-AS NGnCdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLDTWM2OD1zLkC3PVQ4KM7:TR?= MVHTRW5ITVJ?
SW620 NGfnUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;E[XhqUUN3ME2xMlE{PTN2IN88US=> NES4V2VUSU6JRWK=
HuP-T4 NIjrbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX31bo5SUUN3ME2xMlE5OzV7IN88US=> MoHtV2FPT0WU
A549 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDXSGtKSzVyPUGuNVk2PzZizszN MXrTRW5ITVJ?
Mewo NY\Hc4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nrWWlEPTB;MT6yNFI4PiEQvF2= NE\xeWlUSU6JRWK=
ONS-76 M4rhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwMkKwOFkh|ryP NHTOOmZUSU6JRWK=
SK-MEL-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwMkO0NVkh|ryP NVXpfmtOW0GQR1XS
RCM-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDCSI9EUUN3ME2xMlI1ODR5IN88US=> M4focXNCVkeHUh?=
H-EMC-SS M4PoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMkm2NFgh|ryP MlTYV2FPT0WU
NCI-H2291 M4C4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPYTWM2OD1zLkOyOVM3KM7:TR?= MXrTRW5ITVJ?
SW1463 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrwO|dKSzVyPUGuN|M4OjFizszN NInQXVZUSU6JRWK=
LS-411N NEfudlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwNEC1NVch|ryP NWHDXZNHW0GQR1XS
BV-173 M2nJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPzfpJKSzVyPUGuOFQxOTVizszN M4G5e3NCVkeHUh?=
LS-513 NWiwfo9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3VSnVKSzVyPUGuOFUyQTJizszN NX7zTY0xW0GQR1XS
LoVo Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjOTWM2OD1zLkS2N|k6KM7:TR?= Ml7RV2FPT0WU
HO-1-N-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PRRmlEPTB;MT61NVY{PCEQvF2= NEXzU5RUSU6JRWK=
ML-2 M3XZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7iNlVKSzVyPUGuOVI5PjhizszN M1jwc3NCVkeHUh?=
NCI-H1437 NWqxdIR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LLNmlEPTB;MT61OVI4PSEQvF2= NVu5PWZRW0GQR1XS
SW1116 Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TjUGlEPTB;MT61OlM6QCEQvF2= MmXkV2FPT0WU
A4-Fuk MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwNUewOFUh|ryP MV;TRW5ITVJ?
HD-MY-Z M2rsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP5NpVnUUN3ME2xMlU4Ozd4IN88US=> Mm\QV2FPT0WU
SK-MEL-2 NUfLOWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwNUe0OVkh|ryP M1zUfnNCVkeHUh?=
RT-112 M3XRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W2NmlEPTB;MT61PFk2OiEQvF2= MYfTRW5ITVJ?
COLO-829 NX;ad|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzGTWM2OD1zLk[yNlMzKM7:TR?= NYXNR25bW0GQR1XS
OVCAR-5 NYD5WFd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrueIRbUUN3ME2xMlc4Pjh5IN88US=> MXPTRW5ITVJ?
NB69 NHrVPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLIeHk2UUN3ME2xMlc5PDZ7IN88US=> MXPTRW5ITVJ?
NCI-H292 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjvTWM2OD1zLki2Olk6KM7:TR?= MonVV2FPT0WU
LOXIMVI M4rEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvYTWM2OD1zLki5OFI4KM7:TR?= M4jGPHNCVkeHUh?=
BPH-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1izO2lEPTB;MT64PVU6OSEQvF2= MWLTRW5ITVJ?
A375 M3HqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[yZppKSzVyPUGuPFk4OTRizszN MVPTRW5ITVJ?
LCLC-97TM1 NV[zZ|dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;iTYlkUUN3ME2xMlkzOjV4IN88US=> NF3IbpJUSU6JRWK=
RXF393 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LsOWlEPTB;MT65O|g5PyEQvF2= NV35VohUW0GQR1XS
HCC70 M4LmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkTWM2OD1{LkCyOFI3KM7:TR?= MVrTRW5ITVJ?
EM-2 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTRTWM2OD1{LkC3NVk5KM7:TR?= MYrTRW5ITVJ?
MZ2-MEL Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwMUGxNlch|ryP MW\TRW5ITVJ?
HN M3v0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rreWlEPTB;Mj6xOlI4QCEQvF2= M3WyfHNCVkeHUh?=
A2058 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\DRohKSzVyPUKuNVkzPzlizszN M1:zXXNCVkeHUh?=
NB7 M1X0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WyeWlEPTB;Mj6zOFA5PiEQvF2= MWfTRW5ITVJ?
DOK M1;zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwM{W3O|Mh|ryP M1zoNnNCVkeHUh?=
CAL-27 MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[zZmZzUUN3ME2yMlM6OjN4IN88US=> NEi4RZdUSU6JRWK=
BB65-RCC NWHEPFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwNEC2O|Qh|ryP MX7TRW5ITVJ?
RD Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXryWmY{UUN3ME2yMlQ1PzJ|IN88US=> MVTTRW5ITVJ?
KNS-62 M2rETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXpUYNKSzVyPUKuOVEyPjRizszN NYW1d5dMW0GQR1XS
EW-13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P1UWlEPTB;Mj61OlM{QSEQvF2= M2PkTXNCVkeHUh?=
DB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3zTnFKSzVyPUKuOVg4QDhizszN MVfTRW5ITVJ?
HCC2218 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M171VWlEPTB;Mj62OFc4QCEQvF2= MYHTRW5ITVJ?
L-363 NXPPe3BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwN{SzO{DPxE1? NWTHRlJlW0GQR1XS
CHL-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT2TWM2OD1{LkiwO|g2KM7:TR?= M1GwfHNCVkeHUh?=
BFTC-905 MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofWTWM2OD1{LkiyOVMh|ryP M1PHZnNCVkeHUh?=
HCE-T M3fY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJwOEOyOlQh|ryP NYWwN5hCW0GQR1XS
COLO-792 M2DINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T2OmlEPTB;Mj64OFAzPyEQvF2= NED6S|RUSU6JRWK=
LB2241-RCC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvVVZFKSzVyPUKuPFU5QTNizszN MnrYV2FPT0WU
CAL-39 NHTmT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2riWmlEPTB;Mj64PVk6QSEQvF2= NWPucGdyW0GQR1XS
T-24 NIHhOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\hTWM2OD1{LkmxNVEzKM7:TR?= MnnpV2FPT0WU
NCI-H727 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXUcmhKSzVyPUKuPVE4QTZizszN NIHhS2JUSU6JRWK=
Ca9-22 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3cmlEPTB;Mj65O|I2PSEQvF2= M3TvRXNCVkeHUh?=
MIA-PaCa-2 NHTjW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Hre2lEPTB;Mz6wNFc5OSEQvF2= NXXHdFNGW0GQR1XS
HT-1080 M13JTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq5bGxRUUN3ME2zMlAyQTl5IN88US=> NHzjbJVUSU6JRWK=
D-423MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzyWYtNUUN3ME2zMlA4PzV|IN88US=> NIXFe|RUSU6JRWK=
LAMA-84 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwMUO1PEDPxE1? Mli4V2FPT0WU
SW780 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zaZWlEPTB;Mz6xOFIzQSEQvF2= M173RnNCVkeHUh?=
KU-19-19 NVHEV4Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13NTmlEPTB;Mz6xO|A{PCEQvF2= M1P4[nNCVkeHUh?=
COLO-741 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPRTWM2OD1|LkG4Olc{KM7:TR?= NFm1dpJUSU6JRWK=
HSC-3 NVnrdHB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\1cWVKSzVyPUOuNlMyPTFizszN MYXTRW5ITVJ?
SN12C NYTXNYh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fMTmlEPTB;Mz6yOFcxOSEQvF2= MXLTRW5ITVJ?
786-0 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXFPHdkUUN3ME2zMlI4OjR|IN88US=> MlnvV2FPT0WU
GAK MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XuWWlEPTB;Mz6zNlU3OSEQvF2= MXnTRW5ITVJ?
PANC-03-27 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHPcWRIUUN3ME2zMlM2ODR3IN88US=> NVv4Vm1vW0GQR1XS
CTB-1 NEDLXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNwNEewOFch|ryP MorUV2FPT0WU
A427 NEn0So1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K2UGlEPTB;Mz61PVU2PiEQvF2= NYP1Z3NIW0GQR1XS
EGI-1 NUfhcIJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vDemlEPTB;Mz62NFU5OyEQvF2= Mni2V2FPT0WU
U-2-OS M2O3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki5TWM2OD1|Lk[3NlU3KM7:TR?= M4jNcnNCVkeHUh?=
NCI-SNU-5 NYH6WXpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwNke3N{DPxE1? NWr3OnNuW0GQR1XS
SK-LU-1 M1;ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNwNki3PVgh|ryP MVjTRW5ITVJ?
697 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNwNkm2NFMh|ryP M{LuR3NCVkeHUh?=
HPAF-II MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjDdXJKSzVyPUOuO|U1QSEQvF2= MYfTRW5ITVJ?
NCI-H2087 M333WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILjRlJKSzVyPUOuPFQ3PzJizszN M3vUU3NCVkeHUh?=
SK-MEL-3 NGrkV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXmdlJKSzVyPUOuPFUyPTRizszN MUnTRW5ITVJ?
CGTH-W-1 NHPNOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwOEW3NlUh|ryP NVX6eW9KW0GQR1XS
8505C M4S4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXXTWM2OD1|LkmwNFc5KM7:TR?= NEnwN2ZUSU6JRWK=
GAMG M2nzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTRwMEKzO|ch|ryP M4TCcXNCVkeHUh?=
SW626 NGDHXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwMES0PEDPxE1? MYHTRW5ITVJ?
CAL-62 NIThVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;mSmlEPTB;ND6wO|Q{KM7:TR?= MV7TRW5ITVJ?
MHH-PREB-1 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwMUKxNVEh|ryP NF;CfG5USU6JRWK=
RPMI-7951 M1rLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHlTWM2OD12LkK1OVg6KM7:TR?= MUnTRW5ITVJ?
HOP-92 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e1TmlEPTB;ND6yOVY4KM7:TR?= MlzBV2FPT0WU
MDA-MB-231 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mxSGlEPTB;ND6yPVIzOyEQvF2= NW\xcZFpW0GQR1XS
LAN-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;iUJY5UUN3ME20MlMyPjN5IN88US=> MYHTRW5ITVJ?
ALL-PO NH\EeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPobWVKSzVyPUSuN|YyPTZizszN NXvHe3JtW0GQR1XS
HH M{fJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRwNEG1PVch|ryP NFq3NmVUSU6JRWK=
IGROV-1 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTRwNEWxO|Eh|ryP NEDUUoJUSU6JRWK=
NCI-H358 NX7adVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nzTGlEPTB;ND60OVM5PSEQvF2= NFXQV3BUSU6JRWK=
NB5 M1rNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rxfWlEPTB;ND62NFM3QSEQvF2= NE\xbIpUSU6JRWK=
NCI-H747 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;wSGlEPTB;ND62PFgxPyEQvF2= MXfTRW5ITVJ?
NH-12 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PBUGlEPTB;ND63NVYzPSEQvF2= MoizV2FPT0WU
LB1047-RCC NF;wTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRwN{O4NVUh|ryP MXfTRW5ITVJ?
EFO-27 M3\heGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRwN{i2Olch|ryP MVPTRW5ITVJ?
EPLC-272H M{nWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOzO5hKSzVyPUSuPVk3PjlizszN MmPRV2FPT0WU
CAL-54 NXLse5duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqwZ2RMUUN3ME21MlAzPjl3IN88US=> NGGx[mtUSU6JRWK=
H4 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjOTWM2OD13LkC0NlU2KM7:TR?= M1G0N3NCVkeHUh?=
MOLT-13 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDielJKSzVyPUWuNFY4PzZizszN NIXScHJUSU6JRWK=
CAL-33 NUfmS|hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfsNFJ4UUN3ME21MlEzOzF5IN88US=> NFLVUphUSU6JRWK=
23132-87 MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33xSWlEPTB;NT6xOlg4OiEQvF2= MnLqV2FPT0WU
UM-UC-3 M4rjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\GV2lEPTB;NT6xPFA1PyEQvF2= NUfWVYs4W0GQR1XS
HuH-7 NIjofmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jFeWlEPTB;NT6yO|E1PyEQvF2= NF[xfGVUSU6JRWK=
BCPAP MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTVwM{K5Olkh|ryP NV7sZ3pCW0GQR1XS
AsPC-1 M3uyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD1fXE{UUN3ME21MlM3PzZ|IN88US=> MV;TRW5ITVJ?
NCI-H1155 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfSTWM2OD13LkSwNFUyKM7:TR?= NEXSWFdUSU6JRWK=
GT3TKB MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTVwNE[1PVgh|ryP Mn\xV2FPT0WU
HCC2998 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTVwNEmxNFkh|ryP MoD4V2FPT0WU
NUGC-3 NHfwOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTVwNEmzNFIh|ryP MUDTRW5ITVJ?
Hs-578-T Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXruTm5TUUN3ME21MlU{Pzl2IN88US=> MkjVV2FPT0WU
FADU NFL2Oo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLHe3dDUUN3ME21MlU2PzJ4IN88US=> NEjLT3JUSU6JRWK=
NBsusSR MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTVwNUexOVUh|ryP NYD4O5BtW0GQR1XS
ME-180 NGDrfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rTfWlEPTB;NT61PFA6OiEQvF2= MknWV2FPT0WU
SW1710 NFLSfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTVwNkG2OVQh|ryP M1nkV3NCVkeHUh?=
HuP-T3 NFqwOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTZTWM2OD13Lk[yNFI6KM7:TR?= MXTTRW5ITVJ?
HOS NHzYc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\PRWJ{UUN3ME21MlYzQTJ|IN88US=> M13sW3NCVkeHUh?=
PA-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTVwNkSyOlUh|ryP NFPEeopUSU6JRWK=
LU-99A NHftNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXTe5BlUUN3ME21MlY3PDVzIN88US=> Mn\qV2FPT0WU
RS4-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PwTGlEPTB;NT62Olc4PSEQvF2= MoLmV2FPT0WU
TE-8 MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLy[nNLUUN3ME21MlY5PTN5IN88US=> NHPMfnpUSU6JRWK=
RERF-LC-MS NXvaT2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHntNIhKSzVyPUWuOlg5ODNizszN MUPTRW5ITVJ?
MEL-JUSO M{DhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC1b3ZKSzVyPUWuO|M4QCEQvF2= NVz1blVTW0GQR1XS
SK-MES-1 M3\pcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTGTWM2OD13LkizOVI5KM7:TR?= NVjQVmxxW0GQR1XS
D-263MG NUHqWodOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTVwOEizOVEh|ryP NWLkZ2tiW0GQR1XS
NB10 NXHs[|FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPaTWM2OD13Lki5OFYh|ryP MmLqV2FPT0WU
SK-HEP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTVwOUO0O|Eh|ryP MYjTRW5ITVJ?
HT-29 NX3GVnBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDFXYtKSzVyPUWuPVgyOThizszN NW\NcJJbW0GQR1XS
KYSE-140 NVXTeVJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2emlEPTB;Nj6wNlE5OiEQvF2= NIXs[3RUSU6JRWK=
NCI-H1666 NEfwdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3Mb3htUUN3ME22MlA5PDZzIN88US=> NW\0UY1wW0GQR1XS
NCI-H1304 NXTHWHUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTZwMUm5OEDPxE1? NIPWTJBUSU6JRWK=
RPMI-8866 NFvoSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLZTWM2OD14LkKxN|E{KM7:TR?= MY\TRW5ITVJ?
MV-4-11 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PBe2lEPTB;Nj6yN|E6QSEQvF2= NVXTS3BNW0GQR1XS
A431 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnZc5JnUUN3ME22MlI1Ojl4IN88US=> NFzCe3VUSU6JRWK=
PANC-10-05 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfHOHlEUUN3ME22MlI5OzZ|IN88US=> NU[yTWNnW0GQR1XS
TK10 MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDp[2FKSzVyPU[uN|I3ODRizszN MnzrV2FPT0WU
NCI-H1975 NUL1e4c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTZwNEeyNVUh|ryP MWfTRW5ITVJ?
A172 NITSUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTZwNEmxO|Yh|ryP NFrjenpUSU6JRWK=
D-566MG NImzRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S4eWlEPTB;Nj61OFMxOyEQvF2= Mn7pV2FPT0WU
NCI-H2122 NW\qTY1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zoe2lEPTB;Nj62NVUzQCEQvF2= NEW3XJBUSU6JRWK=
COR-L105 NFXL[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7qRm5KSzVyPU[uOlUzPzVizszN M2PoOHNCVkeHUh?=
AN3-CA M4HSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv4d4REUUN3ME22MlY5PjRzIN88US=> MmXDV2FPT0WU
Calu-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jPTWlEPTB;Nj63PVY6QCEQvF2= MnryV2FPT0WU
HCT-116 M1vON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XsWWlEPTB;Nj64NVI3PCEQvF2= MWnTRW5ITVJ?
MHH-NB-11 NWrXTZRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHXTWM2OD14Lki1NFAzKM7:TR?= MUHTRW5ITVJ?
MFE-280 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHBOmZUUUN3ME22Mlg2QTh|IN88US=> MofmV2FPT0WU
SW1088 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTZwOUG5NVMh|ryP MlLNV2FPT0WU
SW48 M3HxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XycWlEPTB;Nj65OFUyKM7:TR?= NFLDUFFUSU6JRWK=
HuCCT1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LyPGlEPTB;Nz6wNVA{PyEQvF2= MVjTRW5ITVJ?
ACHN NV7ve3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXFcW1nUUN3ME23MlAzQTR|IN88US=> Ml\zV2FPT0WU
8305C MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HhWWlEPTB;Nz6wPVk6PSEQvF2= MoPUV2FPT0WU
DoTc2-4510 NUi2Vm9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfvN5RKSzVyPUeuNVIyPSEQvF2= MmrWV2FPT0WU
COR-L23 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LDRWlEPTB;Nz6yOFQzKM7:TR?= M1vLSXNCVkeHUh?=
SK-MEL-30 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnRTWM2OD15LkK1NFg{KM7:TR?= MYrTRW5ITVJ?
BE-13 M2\r[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTdwM{O4N|Qh|ryP NYK4RpI3W0GQR1XS
GR-ST M2nNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTdwNECxO|Qh|ryP Mmm3V2FPT0WU
LU-135 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETJbWdKSzVyPUeuOVU6OzlizszN NWTncJlDW0GQR1XS
U-266 NI\QcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f4NmlEPTB;Nz61OlI5PiEQvF2= MUPTRW5ITVJ?
NCI-H1355 NI\T[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnW[5FKSzVyPUeuOVg3OzVizszN NF7ETWFUSU6JRWK=
NB14 M{niWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTdwNk[2OFIh|ryP NYKxfWI1W0GQR1XS
SCC-25 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLQTWM2OD15LkewPUDPxE1? NVe0b3V4W0GQR1XS
COLO-678 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTdwN{GwO|Yh|ryP NHruOZNUSU6JRWK=
TGBC1TKB Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSwTWM2OD15Lki5N|k5KM7:TR?= NWjiW4pOW0GQR1XS
IST-MEL1 NYC3VodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLqTWM2OD16LkCwOFA3KM7:TR?= M3y2UnNCVkeHUh?=
ECC10 NXu3[XVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H4NGlEPTB;OD6wN|M6PSEQvF2= NFXJO3BUSU6JRWK=
EW-16 NILY[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRThwMEi0OFUh|ryP MWHTRW5ITVJ?
DOHH-2 NXPBW5NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf2eHdYUUN3ME24MlIxODl3IN88US=> M2TVVXNCVkeHUh?=
NCI-H1581 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRThwMk[zNlMh|ryP M3jZdXNCVkeHUh?=
TE-5 NFT1bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHEVGVyUUN3ME24MlQzPDJ7IN88US=> M{GzeXNCVkeHUh?=
CAKI-1 NFvQTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRThwNUeyNlIh|ryP MXXTRW5ITVJ?
A673 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRThwNkOyNFIh|ryP MoTGV2FPT0WU
CAL-12T M4G5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzlPWoyUUN3ME24MlY2PzV|IN88US=> MWTTRW5ITVJ?
DBTRG-05MG NGLOS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRThwN{S4OVkh|ryP M4nTWnNCVkeHUh?=
SK-N-FI MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRThwOEGzO|kh|ryP NXTU[mVjW0GQR1XS
K-562 M3nIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPkXlRKSzVyPUiuPFM6PTdizszN MVTTRW5ITVJ?
SBC-1 NYnOWmhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqxfI9KSzVyPUiuPFY3PDVizszN MUnTRW5ITVJ?
ES4 NVHO[Xk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjnOINKSzVyPUiuPFY5QDRizszN NH\qfGlUSU6JRWK=
MS-1 NFXTXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXmNoJ1UUN3ME24Mlg4PTF5IN88US=> NWDiU2lwW0GQR1XS
RKO M3;GWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHGdWJZUUN3ME24Mlg6ODV5IN88US=> NX;kZoRyW0GQR1XS
NCI-H1693 M{DtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPDW2tKSzVyPUiuPVIyPyEQvF2= NUi4fIRnW0GQR1XS
SW954 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnDTWM2OD16Lkm2PVc5KM7:TR?= MkHPV2FPT0WU
SK-UT-1 NXjiV204T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRThwOUe2PFMh|ryP M3myWHNCVkeHUh?=
T98G NHzaZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRThwOUm4OFYh|ryP NV7oWWpJW0GQR1XS
NCI-H2126 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnBdohKSzVyPUmuNFA5OjZizszN NX;5N2Z4W0GQR1XS
TE-12 M2HrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTlwMEOzOlch|ryP NEGxOJlUSU6JRWK=
DK-MG NIrWe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTlwMkGxPVEh|ryP MlvsV2FPT0WU
MEG-01 NEHjTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvqTWM2OD17LkK0PVMyKM7:TR?= NVnt[pZVW0GQR1XS
HCC1937 NGL3O4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDrRlN[UUN3ME25MlI6ODlzIN88US=> NVOxR|RvW0GQR1XS
MKN45 MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn4[I5KSzVyPUmuOFUxPjVizszN M1LKSnNCVkeHUh?=
NCI-H1792 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TKR2lEPTB;OT60OVIyQSEQvF2= NIT5TYJUSU6JRWK=
SW1417 M1W1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnGcpNNUUN3ME25MlU3QDN5IN88US=> Mn6wV2FPT0WU
639-V NH\sfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HXN2lEPTB;OT62OFM5QCEQvF2= NHe0N2xUSU6JRWK=
P30-OHK NHPNNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHNTWM2OD17Lk[1N|E3KM7:TR?= MYrTRW5ITVJ?
YKG-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPuN2RKSzVyPUmuO|UxOzNizszN MVLTRW5ITVJ?
KGN NGr5WmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7uTWM2OD17LkizO|k2KM7:TR?= NFu0PI9USU6JRWK=
MSTO-211H NHe0TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hwc2lEPTB;OT65OVUzQSEQvF2= MoH0V2FPT0WU
NCI-H1573 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG2RodKSzVyPUGwMlE2PzRizszN MUfTRW5ITVJ?
NCI-H720 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXnTWM2OD1zMD6xPVg6KM7:TR?= M1;D[XNCVkeHUh?=
KARPAS-45 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rRfWlEPTB;MUCuNlc6PSEQvF2= MkiyV2FPT0WU
MDA-MB-175-VII MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFyLkS4JO69VQ>? NU\nZVZ4W0GQR1XS
SK-NEP-1 NUe0d|RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\1WGlEPTB;MUCuOFk5OSEQvF2= MnvQV2FPT0WU
MKN28 NHHvXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP1TWM2OD1zMD61NVgh|ryP M3rwdXNCVkeHUh?=
KYSE-520 MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFyLkWyJO69VQ>? MVzTRW5ITVJ?
KE-37 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPsTWM2OD1zMD61NlczKM7:TR?= NXPzSoE5W0GQR1XS
VA-ES-BJ MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXBTWM2OD1zMD61Olch|ryP NEDXOGNUSU6JRWK=
CCRF-CEM NHHGO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nJTmlEPTB;MUCuOVY5PCEQvF2= NFzLTVFUSU6JRWK=
GMS-10 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFyLk[wPVQh|ryP MWXTRW5ITVJ?
NCI-H1623 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\y[WtKSzVyPUGwMlY{PzlizszN NWjORoZsW0GQR1XS
NEC8 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nVe2lEPTB;MUCuO|c4OyEQvF2= M3u2XXNCVkeHUh?=
MOLT-16 NWXoZodET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFyLkixNVMh|ryP NWDqR|BSW0GQR1XS
DJM-1 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGwcWZqUUN3ME2xNU4xOzd7IN88US=> MnLFV2FPT0WU
U251 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfaT481UUN3ME2xNU4xPDJizszN MY\TRW5ITVJ?
SBC-5 NVry[XRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW5ephoUUN3ME2xNU4yPDZ5IN88US=> MoTCV2FPT0WU
SW756 NXHtcotST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluwTWM2OD1zMT6yNVU1KM7:TR?= NEL5d|VUSU6JRWK=
KS-1 NWLU[GFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3STWM2OD1zMT6yOlE6KM7:TR?= NXToXoFHW0GQR1XS
SF295 NGLme|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnyTmlWUUN3ME2xNU4{OTB2IN88US=> MXrTRW5ITVJ?
YH-13 M2XUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXWTWM2OD1zMT6zNlY4KM7:TR?= MUPTRW5ITVJ?
SW837 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H3UGlEPTB;MUGuN|UxPiEQvF2= MUnTRW5ITVJ?
KYSE-450 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHa[WR{UUN3ME2xNU41ODV5IN88US=> NEDoW|JUSU6JRWK=
KYSE-180 NEDlSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rN[WlEPTB;MUGuOFgzKM7:TR?= NGS1RZdUSU6JRWK=
S-117 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7WTWM2OD1zMT60PFk3KM7:TR?= M3v3NHNCVkeHUh?=
KOSC-2 NXK3eYtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzw[IVKSzVyPUGxMlYzOjJizszN MWrTRW5ITVJ?
KYSE-270 NYnNdFc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnMNoJKSzVyPUGxMlg4PDVizszN MYrTRW5ITVJ?
D-336MG M4P1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3KZ21FUUN3ME2xNU46ODd3IN88US=> MoPFV2FPT0WU
KALS-1 M1Xwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTxNGFKSzVyPUGyMlAxOTZizszN MUnTRW5ITVJ?
LB373-MEL-D MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjlPYgyUUN3ME2xNk4xPTN|IN88US=> NFzo[2tUSU6JRWK=
HLE M3XWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;lWG5KSzVyPUGyMlA2QDVizszN MWPTRW5ITVJ?
SJSA-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTj[pRLUUN3ME2xNk4xPzN3IN88US=> NIric5JUSU6JRWK=
SW1990 M1rIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHewOItKSzVyPUGyMlA6OTFizszN M3rBVnNCVkeHUh?=
NOS-1 NUP4e3FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT3c5ZKSzVyPUGyMlE{PTJizszN M2XObnNCVkeHUh?=
GI-ME-N M2nIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHztbnNKSzVyPUGyMlIyPjNizszN NXT1TlRlW0GQR1XS
NCI-H1703 M4LY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\IfGhwUUN3ME2xNk4zPjF4IN88US=> Ml:5V2FPT0WU
ES7 M4PvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF{LkK3NlQh|ryP M1q0dXNCVkeHUh?=
KYSE-510 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID0d2FKSzVyPUGyMlUxPzlizszN NELGO5hUSU6JRWK=
BHY NV\odJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Tud2lEPTB;MUKuOVMxPyEQvF2= NFTCbFNUSU6JRWK=
TCCSUP MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTiU3l4UUN3ME2xNk42PzV5IN88US=> NGS5Z45USU6JRWK=
HSC-2 NUTyfnZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2xTWM2OD1zMj61PVk3KM7:TR?= Mnq5V2FPT0WU
BEN MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u5TGlEPTB;MUKuOlE1OyEQvF2= Mn20V2FPT0WU
769-P M2PmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37pSmlEPTB;MUKuO|kzPCEQvF2= Mk\vV2FPT0WU
HT M3nKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M130XGlEPTB;MUKuPFM1PiEQvF2= NV3SU45{W0GQR1XS
LXF-289 M2PGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfYZohKSzVyPUGyMlk2OzFizszN MmK1V2FPT0WU
OVCAR-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nGVmlEPTB;MUKuPVU3PyEQvF2= MX;TRW5ITVJ?
ATN-1 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTpb2FKSzVyPUGzMlAyQDRizszN NWHJZYpPW0GQR1XS
8-MG-BA NUntPZdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPZeolKSzVyPUGzMlA1PTVizszN NXXOZXp5W0GQR1XS
SW13 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF|LkGxOlUh|ryP Mor5V2FPT0WU
NCI-H1092 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTYTWM2OD1zMz6xOlIh|ryP NHTnUGlUSU6JRWK=
OAW-42 NWrIU4J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K5emlEPTB;MUOuNVk{PyEQvF2= MXfTRW5ITVJ?
NCI-H2452 NXK5UlRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvyNplTUUN3ME2xN{4zOTd3IN88US=> M2jXXXNCVkeHUh?=
CAPAN-1 NHjYVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF|LkW1NVQh|ryP Mo\MV2FPT0WU
NCI-H2009 NX\SdXJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj3blJKSzVyPUGzMlU6OTlizszN NWHLSXBoW0GQR1XS
SF268 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF|Lk[zNlYh|ryP M2jySXNCVkeHUh?=
GCIY Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O2NmlEPTB;MUOuOlkzPyEQvF2= NGOwVXZUSU6JRWK=
OS-RC-2 NFq3XY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi1Xm5KSzVyPUGzMlk2ODFizszN NF\VbJZUSU6JRWK=
GCT NHzMeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LGR2lEPTB;MUOuPVY6PyEQvF2= NX7YPHdzW0GQR1XS
NB17 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDVN5dtUUN3ME2xOE4xQDVizszN MV3TRW5ITVJ?
NCI-H2030 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fONmlEPTB;MUSuNVQ3PSEQvF2= MW\TRW5ITVJ?
HC-1 M3Hnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3roO2lEPTB;MUSuNlA5PyEQvF2= MmrwV2FPT0WU
QIMR-WIL MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrOTZRNUUN3ME2xOE4{PDF{IN88US=> NHfxdmlUSU6JRWK=
Capan-2 M1viXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr5fZhqUUN3ME2xOE4{PzF2IN88US=> MXTTRW5ITVJ?
BALL-1 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDWdJdKSzVyPUG0MlQ3PjVizszN M3fWXHNCVkeHUh?=
LS-1034 NHHxOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW1TWM2OD1zND62NVUzKM7:TR?= M{PESXNCVkeHUh?=
U-118-MG NIK4[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjSeVI3UUN3ME2xOE43OzFizszN MlnzV2FPT0WU
NCI-H630 NH7vR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HVXmlEPTB;MUSuOlU3QCEQvF2= NEXUcWdUSU6JRWK=
OVCAR-8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHvcFlKSzVyPUG0MlczODFizszN MWfTRW5ITVJ?
NCI-H2347 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jh[2lEPTB;MUSuPFI{KM7:TR?= M1na[nNCVkeHUh?=
BT-549 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDnTWM2OD1zND64Nlg1KM7:TR?= M1zXOXNCVkeHUh?=
LB831-BLC NULaXZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF2Lki5N|Qh|ryP NETsWHlUSU6JRWK=
NCI-H661 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELSbG1KSzVyPUG0Mlk2QSEQvF2= MX3TRW5ITVJ?
MKN7 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjrO4FKSzVyPUG1MlAxQTNizszN NVTVeGhzW0GQR1XS
U-87-MG MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TJOWlEPTB;MUWuNFg6PyEQvF2= NVTnZW5sW0GQR1XS
OVCAR-4 NYX4bmY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XSWmlEPTB;MUWuNVQzPCEQvF2= NVvTV2V7W0GQR1XS
OE33 NFvxW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon3TWM2OD1zNT6xO|EyKM7:TR?= MW\TRW5ITVJ?
EC-GI-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn6dJgyUUN3ME2xOU4zOzV5IN88US=> M{HMOXNCVkeHUh?=
AM-38 NHnxRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrYTWM2OD1zNT6yO|E4KM7:TR?= MUPTRW5ITVJ?
NCI-H1563 NUXMcpM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X5O2lEPTB;MUWuN|Q6KM7:TR?= MWLTRW5ITVJ?
SCC-4 NI\QWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\6cmlEPTB;MUWuOFExOyEQvF2= MWHTRW5ITVJ?
Detroit562 NVPRd41uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LrdWlEPTB;MUWuOFU1PyEQvF2= NEfDe4ZUSU6JRWK=
PC-14 M4rUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrHVlNVUUN3ME2xOU41QDZ4IN88US=> NIHVSVhUSU6JRWK=
ES3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjP[5VWUUN3ME2xOU42OzZizszN M2fxdHNCVkeHUh?=
OCI-AML2 NGe0SopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzYTWM2OD1zNT63OlE1KM7:TR?= NUjlT3E6W0GQR1XS
LU-134-A NXzKWW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlTWM2OD1zNT65NFE5KM7:TR?= MXPTRW5ITVJ?
SAS NIfVRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;POGlEPTB;MUWuPVM4OyEQvF2= M3Kz[HNCVkeHUh?=
TGBC11TKB M4LZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj1[ItKSzVyPUG1Mlk1OTRizszN NWXKfG52W0GQR1XS
HOP-62 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGeySoNKSzVyPUG1Mlk2QTdizszN NX70fGRGW0GQR1XS
G-401 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj4dIFKSzVyPUG1Mlk3PDlizszN MUXTRW5ITVJ?
NCI-H28 NYjHTpFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF4LkC4OVYh|ryP MVnTRW5ITVJ?
A204 M2TsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXXZVRUUUN3ME2xOk4zODB4IN88US=> NEHT[o5USU6JRWK=
NCI-H1299 NWe2bVVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi5ZWcyUUN3ME2xOk4zOjlzIN88US=> M1rUXHNCVkeHUh?=
VMRC-RCZ M3;Edmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\DTWM2OD1zNj6yOVkzKM7:TR?= M4rRUHNCVkeHUh?=
BxPC-3 M3jtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG4TWM2OD1zNj6yPFU3KM7:TR?= MnPvV2FPT0WU
NCI-H2228 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF4LkWxOVgh|ryP MX;TRW5ITVJ?
NCI-H23 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nsOWlEPTB;MU[uOlA4QCEQvF2= NUnuVpN2W0GQR1XS
NKM-1 NF3PU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nUe2lEPTB;MUeuNFE5QSEQvF2= NGXx[JVUSU6JRWK=
KYSE-70 NHjLU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LtTGlEPTB;MUeuNlg6KM7:TR?= MWfTRW5ITVJ?
BB49-HNC NXruWpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnhTlJ{UUN3ME2xO{42Pjh4IN88US=> NF22To9USU6JRWK=
SCC-15 NYrn[XlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHhWJlKSzVyPUG3Mlg1PzNizszN NGXtOYxUSU6JRWK=
D-247MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzVTWM2OD1zNz65NlQ4KM7:TR?= MlnEV2FPT0WU
BB30-HNC M{L5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLzTWM2OD1zOD6wN|E5KM7:TR?= NGnjPGRUSU6JRWK=
CAL-85-1 NU\KW|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDqWlR6UUN3ME2xPE4yQDB7IN88US=> NXr3WWwyW0GQR1XS
HT-3 NYXke4RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXOPYp3UUN3ME2xPE4{QTd5IN88US=> MmW2V2FPT0WU
KYSE-410 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7qTWM2OD1zOD60OVc4KM7:TR?= NET3RldUSU6JRWK=
SW982 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK3TWM2OD1zOD61OlQ6KM7:TR?= MnXVV2FPT0WU
SW962 NVPDNnB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PIWmlEPTB;MUiuOVcxOiEQvF2= MnHmV2FPT0WU
Ramos-2G6-4C10 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\sVmN[UUN3ME2xPE42QTJ5IN88US=> MX;TRW5ITVJ?
OC-314 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF6LkezPFQh|ryP MUXTRW5ITVJ?
LS-123 M2XZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLGTWM2OD1zOD63PVAyKM7:TR?= NVvlPGk5W0GQR1XS
D-502MG Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fDdmlEPTB;MUiuPFE{QSEQvF2= M1:3Z3NCVkeHUh?=
RO82-W-1 M3P0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrlRYxzUUN3ME2xPE45Ojh6IN88US=> NXrBPFNDW0GQR1XS
HuO9 NFHCXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF7LkGzO|kh|ryP MWDTRW5ITVJ?
ETK-1 NYnOZWx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjG[ZhKSzVyPUG5MlE5OjdizszN MYLTRW5ITVJ?
SNU-387 M1\w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXw[ohKSzVyPUG5MlE5QDlizszN MYLTRW5ITVJ?
SW1573 NH7QbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTKTWM2OD1zOT6xPVY6KM7:TR?= M4fmPXNCVkeHUh?=
NTERA-S-cl-D1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DvemlEPTB;MUmuNlAxPyEQvF2= M4fnPXNCVkeHUh?=
SF126 M3nIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PFN2lEPTB;MUmuN|UxOiEQvF2= Mme5V2FPT0WU
Calu-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[we4ZKSzVyPUG5MlQzOzdizszN MXTTRW5ITVJ?
NCI-H1048 NEXYb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe0foIxUUN3ME2yNE4{OjZ4IN88US=> MX;TRW5ITVJ?
NCI-H226 M4D1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPrTWM2OD1{MD60N|k6KM7:TR?= M{K0TnNCVkeHUh?=
FTC-133 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrZdopKSzVyPUKwMlQ4ODNizszN M3:2dHNCVkeHUh?=
SF539 NHT6NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TyN2lEPTB;MkCuOVE4OiEQvF2= M13RfnNCVkeHUh?=
TE-6 NInwbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC1cpBZUUN3ME2yNE45ODZ5IN88US=> MkjTV2FPT0WU
UMC-11 NUPkNIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLzTWM2OD1{MD65NVY1KM7:TR?= MVzTRW5ITVJ?
Becker MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfKXVJKSzVyPUKxMlEyOThizszN NE\MeIRUSU6JRWK=
KP-4 NX7SWXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJzLkGxPVYh|ryP Mke0V2FPT0WU
ChaGo-K-1 NV\nenhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJzLkO2Nlch|ryP MnfDV2FPT0WU
CFPAC-1 M4PRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LtXWlEPTB;MkGuN|g2QCEQvF2= MUPTRW5ITVJ?
A498 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH36XHRKSzVyPUKxMlU{OTJizszN NX20Olc4W0GQR1XS
NCI-H1755 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e1SWlEPTB;MkGuOlc1OSEQvF2= NFPVWYhUSU6JRWK=
TI-73 M{fnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnnTWM2OD1{Mj6zNlgh|ryP MmrVV2FPT0WU
NCI-H441 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ{LkW2PFkh|ryP M3fne3NCVkeHUh?=
CaR-1 NIewZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nKb2lEPTB;MkOuNFIyOyEQvF2= Mn;2V2FPT0WU
HCC1806 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7HTo9rUUN3ME2yN{4xPTh|IN88US=> NF\HTlhUSU6JRWK=
SNU-449 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX0PI9EUUN3ME2yN{4{OjlizszN MmjpV2FPT0WU
EKVX MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX24OGlwUUN3ME2yN{4{QTB7IN88US=> NGXLbllUSU6JRWK=
DMS-114 NX\VR4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGzTWM2OD1{Mz61O|Y2KM7:TR?= MlfhV2FPT0WU
A704 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\WOodKSzVyPUKzMlYyODNizszN M{XEXHNCVkeHUh?=
LC-2-ad NVLvOXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnNfYI5UUN3ME2yN{43OTR5IN88US=> NF\HR5hUSU6JRWK=
VM-CUB-1 NITvUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DM[mlEPTB;MkOuO|M1OSEQvF2= MUTTRW5ITVJ?
PC-3 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HKUmlEPTB;MkSuNFUzPiEQvF2= MmLsV2FPT0WU
HEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ2LkC4OlUh|ryP NVf2fHdwW0GQR1XS
ABC-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDQW4lwUUN3ME2yOE4zPzJ7IN88US=> MXPTRW5ITVJ?
COLO-680N Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf6TWM2OD1{ND60O|Y1KM7:TR?= MkTTV2FPT0WU
MZ1-PC M1PuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHL[W5nUUN3ME2yOE43QDdizszN MV\TRW5ITVJ?
NCI-H69 NEL5ToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJ2LkezOVQh|ryP MnX0V2FPT0WU
TE-1 NWnEOoFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr2TWM2OD1{NT6wOFk6KM7:TR?= Mor5V2FPT0WU
EW-3 M2DDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ3LkGxN{DPxE1? NVrESI9lW0GQR1XS
PANC-08-13 NWjsVm5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPNTWM2OD1{NT64NVA{KM7:TR?= Mm\0V2FPT0WU
NMC-G1 M3LzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fJSWlEPTB;Mk[uNFA5QCEQvF2= NIWzNpVUSU6JRWK=
BT-20 NEHYS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojhTWM2OD1{Nj60OVQ{KM7:TR?= M1LFPHNCVkeHUh?=
TGBC24TKB MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXD[4FKUUN3ME2yOk44OzNzIN88US=> NHL4PGZUSU6JRWK=
TE-11 MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJ4Lkm4PVUh|ryP M4W2SnNCVkeHUh?=
ESS-1 NILtOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX70VXdoUUN3ME2yO{4{OjF4IN88US=> M{LmZnNCVkeHUh?=
JVM-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrPTWM2OD1{Nz62OFc2KM7:TR?= MXzTRW5ITVJ?
C3A NEfkXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorBTWM2OD1{Nz64OFk3KM7:TR?= MnXUV2FPT0WU
MDA-MB-157 M362Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFniTFhKSzVyPUK3Mlg4PTNizszN NW\yO2dmW0GQR1XS
KLE MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ6LkGwOVgh|ryP MUnTRW5ITVJ?
ES1 Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HTemlEPTB;MkiuNVg{QCEQvF2= MoX2V2FPT0WU
CAL-120 NHGxdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3DfWtKSzVyPUK4MlM6QTlizszN MUHTRW5ITVJ?
NCI-N87 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJ6LkWxNFUh|ryP NGXrbHZUSU6JRWK=
RPMI-8226 NGHURYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W0TGlEPTB;MkmuNVg1OyEQvF2= MoroV2FPT0WU
COR-L88 M1rGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32zfmlEPTB;MkmuNlQyQSEQvF2= M1K5c3NCVkeHUh?=
UACC-893 NF75SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ7LkOxN|ch|ryP Mn3uV2FPT0WU
C8166 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ7Lkm5PVYh|ryP NIDOfJlUSU6JRWK=
J82 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNyLkixOFch|ryP M4X3WHNCVkeHUh?=
PFSK-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTVV3NDUUN3ME2zNU4xPjV7IN88US=> NXPzNIM3W0GQR1XS
COLO-684 NXriZY1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW2TWM2OD1|MT60N|c1KM7:TR?= MlXRV2FPT0WU
CAL-72 M4HXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW1T2FFUUN3ME2zNU42PzJ7IN88US=> NX64bpVLW0GQR1XS
SNB75 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XFemlEPTB;M{GuPFk4KM7:TR?= M3zxSHNCVkeHUh?=
MDA-MB-415 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNzLkm3OlIh|ryP NX\Dco1TW0GQR1XS
SiHa M{LPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zGN2lEPTB;M{KuOFcyOSEQvF2= NE\GNpJUSU6JRWK=
NCI-H1648 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme5TWM2OD1|Mj65N|Q2KM7:TR?= M{H6S3NCVkeHUh?=
EFO-21 M1\y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4naWWlEPTB;M{OuNFA2KM7:TR?= NXT6S4E{W0GQR1XS
HCC38 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN|LkO4OFEh|ryP NEfnU2FUSU6JRWK=
IA-LM NH\kNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;xUm9KSzVyPUOzMlc5QDlizszN M1PIRXNCVkeHUh?=
CTV-1 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jIb2lEPTB;M{OuPVc5PiEQvF2= NX\OdW5SW0GQR1XS
NCI-H446 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTN2LkK2PFkh|ryP MVjTRW5ITVJ?
IST-SL1 NHfLdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN2Lke0NFgh|ryP Mle3V2FPT0WU
EW-22 NGXvXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfr[nRKSzVyPUO0Mlc4PTlizszN NEDOVpNUSU6JRWK=
JEG-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN4LkG3OlYh|ryP MVvTRW5ITVJ?
LU-65 M4LodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXMSnFKSzVyPUO2MlI6QDVizszN NWrQWGpYW0GQR1XS
NCI-H596 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN4Lkm1PVEh|ryP MnrWV2FPT0WU
KNS-81-FD MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjiPXVKSzVyPUO3MlE1PSEQvF2= MWHTRW5ITVJ?
NCI-H1793 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN5LkewPFYh|ryP MX7TRW5ITVJ?
NCI-H460 MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfmTWM2OD1|OD6wPFc{KM7:TR?= NV\zRXk5W0GQR1XS
MPP-89 NH\aRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP6TWM2OD1|OT61PFg3KM7:TR?= NH:zZohUSU6JRWK=
D-542MG NYf2bnBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN7Lki0N|Yh|ryP NVHEUWp6W0GQR1XS
JAR Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfofGtZUUN3ME20NE41PzB3IN88US=> M3jkenNCVkeHUh?=
NCI-H209 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRyLk[3O{DPxE1? MofBV2FPT0WU
G-402 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHlWpp7UUN3ME20NU4{QTl|IN88US=> NWfBXY5TW0GQR1XS
IST-MES1 NWDu[412T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHCN5BpUUN3ME20Nk4yQTN3IN88US=> MWDTRW5ITVJ?
Daoy NUHjelZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPHZZA{UUN3ME20Nk42PDdzIN88US=> NWCzNWk3W0GQR1XS
EW-11 M1HxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\mfXl6UUN3ME20N{4yOjFzIN88US=> MmWxV2FPT0WU
Saos-2 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR|LkG1N|ch|ryP NX;q[HU1W0GQR1XS
no-10 NGTzRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ewSWlEPTB;NEOuNVcxOiEQvF2= NWLjNmYyW0GQR1XS
HCC1395 M1LCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLrTWM2OD12Mz60OlQ1KM7:TR?= M4\mVnNCVkeHUh?=
HCE-4 M2PPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTR|Lke2OlQh|ryP NEPJWnBUSU6JRWK=
EW-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmwTWM2OD12Mz64NFQ6KM7:TR?= MYPTRW5ITVJ?
OCUB-M NGDzXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO0eXVKSzVyPUS0MlM3OzhizszN Mk\TV2FPT0WU
IGR-1 NVjPfIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\oVmlEPTB;NESuOFEyPSEQvF2= NVTXfXhlW0GQR1XS
NCI-H1838 NVjzbnFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC0R3NzUUN3ME20OE41OzR7IN88US=> Ml;NV2FPT0WU
NCI-H2405 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR2LkWzOEDPxE1? MoD5V2FPT0WU
GB-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7kTWM2OD12ND63OFY{KM7:TR?= NIW5c|RUSU6JRWK=
MG-63 M1zPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTR4LkC2PVYh|ryP M1\nT3NCVkeHUh?=
KP-N-YN M2TDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzBTWM2OD12Nj60Olc6KM7:TR?= M4\lN3NCVkeHUh?=
no-11 NUCySYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm2VnhEUUN3ME20O{4xOjR2IN88US=> M33FfXNCVkeHUh?=
SW948 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPRfI5yUUN3ME20O{4{Ozd5IN88US=> NH;QO4FUSU6JRWK=
CAMA-1 Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33RXGlEPTB;NEeuN|Q{QCEQvF2= M3j3RXNCVkeHUh?=
HCC1187 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHkTWM2OD12Nz61NUDPxE1? M331VXNCVkeHUh?=
D-392MG M1Xi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTR5Lk[1NVYh|ryP M2HmUHNCVkeHUh?=
647-V NXzMdnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;k[GlEPTB;NEmuN|QyPCEQvF2= M{HnSnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID